drugset / Trial / NCT03027934

A Single Center Study to Evaluate Ticagrelor Mechanism of Action in Inhibiting Juvenile Platelet ADP Response

NCT03027934

Phase 4 Withdrawn CirQuest Labs, LLC
RandomizedCrossoverOpen-labelBasic science

Summary

The overall objective of this study is to assess P2Y12 inhibition ex vivo in blood samples obtained from diabetic subjects who will be administered one of the two P2Y12 antagonists in a cross-over design.

Timeline

Start
2017-08-28
Primary completion
2017-10-31
Completion
2017-10-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Prasugrel Small molecule 10 mg
Comparator Ticagrelor Small molecule 90 mg

Indications